JNJ

NYSE Healthcare

Johnson & Johnson Common Stock

Drug Manufacturers - General

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

๐Ÿ“Š Market Data
Price$227.19
Volume6,022,437
Market Cap546.90B
Dividend Yield %2.36%
Beta0.330
RSI (14-Day)34.2
200-Day MA$204.79
50-Day MA$238.46
52-Week High$251.71
52-Week Low$146.12
P/E Ratio26.33
Forward P/E17.87
Price / Book6.73
๐ŸŽฏ Investment Strategy Scores

JNJ scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 74/100โ–ฒ +1
High dividend yield + low volatility
๐Ÿš€ Moon Shot 42/100โ–ฒ +4
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 69/100โ–ฒ +1
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 9/100โ–ฒ +1
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ‹ Institutional Whale (99/100) โ€” this strategy Large-cap, institutional-quality stocks.

Lowest fit among scored strategies: ๐ŸŽˆ Over-Hyped (9/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find JNJ in your text

Paste any article, transcript, or post โ€” the tool will extract JNJ and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.